Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Lumiliximab with FCR · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Lumiliximab with FCR | DRUG | Dose, schedule, and duration specified in protocol |
Inclusion Criteria: * Age: 18 years and older * Diagnosis of B-cell CLL by International Workshop on CLL (IWCLL) response criteria * Relapsed CD23+ B-cell CLL * Rai Stage III or IV, or Rai Stage I or II if determined to have disease progression as evidenced by rapid doubling or peripheral lymphocyt...
Lumiliximab with FCR is used for the treatment of chronic lymphocytic leukemia (CLL). It is specifically being studied in patients with relapsed CLL. The combination therapy is intended to address this blood cancer, which affects lymphocytes and can recur after initial treatment.
Lumiliximab with FCR is being developed by Biogen Inc., a biotechnology company traded on the NASDAQ under the ticker symbol BIIB. Biogen is responsible for the clinical development of this combination therapy for chronic lymphocytic leukemia.
Lumiliximab with FCR is in Phase 1 clinical development. It is an investigational combination therapy, meaning it has not been approved by regulatory authorities and is still being studied in clinical trials to evaluate its safety and efficacy in patients with relapsed chronic lymphocytic leukemia.
Lumiliximab with FCR has one completed clinical trial, identified as NCT00103558. This Phase 1 study, titled 'Lumiliximab in Combination With FCR in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL),' enrolled 31 participants in the United States. The trial was uncontrolled and not randomized, and it included adults aged 18 years and older.
Lumiliximab with FCR is not FDA approved. It is an investigational combination therapy currently in Phase 1 clinical development for chronic lymphocytic leukemia. The drug has not completed the clinical trial process necessary to establish safety and efficacy for regulatory approval.